Search results
Results from the WOW.Com Content Network
Common side effects include headache, diarrhea, dizziness, and cough. [2] Serious side effects may include decreased survival in those with heart failure, low platelets, and low white blood cells. [2] Cilostazol is a phosphodiesterase 3 inhibitor which works by inhibiting platelet aggregation and dilating arteries. [2]
Cilostazol is used for the treatment of intermittent claudication. This drug has a much weaker positive inotropic effect than those drugs used for the therapy of acute heart failure, and lacks significant adverse cardiac effects.
Cardiotonic agents, also known as cardiac inotropes or stimulants, have a positive impact on the myocardium (muscular layer of the heart) by enhancing its contractility. . Unlike general inotropes, these agents exhibit a higher level of specificity as they selectively target the myocar
Antiplatelet drugs effect may be affected by patient's medications, current medical conditions, food and supplements taken. Antiplatelet drugs effect may be increased or decreased. An increase in antiplatelet effect would increase the risk of bleeding and could cause prolonged or excessive bleeding.
Hepatotoxicity, dermatological side effects, and abuse potential. [7] Aminopyrine: 1999 France, Thailand Risk of agranulocytosis and severe acne. [3] Amobarbital: 1980 Norway Risk of barbiturate toxicity. [3] Amoproxan: 1970 France Dermatologic and ophthalmic toxicity. [3] Anagestone acetate: 1969 Germany Animal carcinogenicity. [3] Antrafenine ...
The effects of amrinone vary widely with species and experimental condition; therefore, its inotropic effects are variable. [3] A loss in sensitivity to phosphodiesterase 3 inhibitors, including amrinone, has been observed in end stage heart failure in humans; other treatment options may be more useful for improvement in these stages.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
HT-0712, also known as IPL-455903, [1] is an experimental cognitive enhancing drug which is currently undergoing clinical trials.It is currently being licensed by Helicon Therapeutics in San Diego, California.